Apogee Therapeutics reported Phase II maintenance results showing durable skin‑clearance with its anti‑IL‑13 antibody zumilokibart (zumi) using three‑ and six‑month dosing schedules. The mid‑stage readout showed high rates of sustained EASI‑75 responses at one year, prompting analysts to raise peak‑sales forecasts and send shares sharply higher. The company argues the data demonstrate potential differentiation versus existing biologics by enabling much less frequent dosing. The results will require confirmation in larger, registrational trials, but the readout intensifies competition in atopic dermatitis and underscores investor appetite for long‑acting biologics that reduce treatment burden.